BriaCell Reports Strong Survival and Clinical Benefits at ASCO 2025
June 4, 2025
Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients